PONIARD PHARMACEUT

As of September 30, 2011, PONIARD PHARMACEUT carries a market capitalization of 7.49M, placing it among publicly traded companies globally. Its enterprise value stands at 7.15M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of September 30, 2011, PONIARD PHARMACEUT has 1.50M shares outstanding.

These figures are as of September 30, 2011.

As of September 30, 2011, PONIARD PHARMACEUT maintains a current ratio of 0.76, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 52.61, indicating elevated leverage, while an interest coverage ratio of -26.60 demonstrates limited ability to service its debt obligations.

Over the twelve months ended September 30, 2011, PONIARD PHARMACEUT posted a negative return on equity (ROE) of -212.95, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -82.52, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 8.00, a quick read on workforce productivity versus industry peers.

As of the close on October 9, 2026, PONIARD PHARMACEUT's stock has gained approximately 0.00% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.04.

Over the twelve months ended September 30, 2011, PONIARD PHARMACEUT generated - - in revenue and converted that into -16.04M in net income, yielding earnings per share of -11.56. EBITDA reached -14.26M, while operating income came in at -15.53M.

As of September 30, 2011, PONIARD PHARMACEUT holds 1.98M in cash and equivalents against 1.64M in total debt, resulting in a net debt position of -1.98M. Total book value stands at 3.12M, with working capital of -727,000.00 providing operational flexibility.

PONIARD PHARMACEUT produced -10.46M in operating cash flow over the twelve months ended September 30, 2011. After subtracting -9,000.00 in capital expenditures, free cash flow totaled -10.47M - equivalent to -7.54 per share.

These figures cover the twelve months ended September 30, 2011. The dividend payout ratio of 1.18 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -150.78: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 144.23, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to PONIARD PHARMACEUT shareholders.

PONIARD PHARMACEUT's most recent stock split took place on November 23, 2011 with a 40:1 split ratio.

As of September 30, 2011, PONIARD PHARMACEUT has an Altman Z-Score of -299.50, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.